Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| With ACP-204 we're seeking to build on our extensive learnings from pimavanserin and believe it has an exciting future |
| We are seeing improvements in persistency as patients and HCPs gain more experience with the safety and tolerability profile of DAYBUE |
| Looking to this year and beyond, we continued to capitalize on the successful launch of DAYBUE and project strong revenue streams from DAYBUE and NUPLAZID |
| And then as part is peak sales is concerned, we obviously see meaningfully improvement in sales this year as per our guidance |
| We're proud of our early success with the launch and excited about the future of DAYBUE |
| NUPLAZID continued to deliver and be strongly cash flow positive |
| Sales in the fourth quarter were $143.9 million and reflect our ability to gain market share and grow the revenue base while continuing to manage the expense base |
| In addition to our two successful commercial franchises, we have a deep and growing pipeline which is making significant advances, including programs in the negative symptoms of schizophrenia, Prader-Willi syndrome and Alzheimer's disease psychosis |
| And in February we have seen strong recovery across these metrics |
| We delivered 40% revenue growth in 2023 on the strength of our successful DAYBUE launch |
| And then in February, we saw a significant rebound in new patient starts and together with improvements in conversion and refill rates |
| Our NUPLAZID franchise achieved 3% demand bottle growth year-over-year, driven by increases in new patient starts in both market segments |
| ACADIA is relatively unique amongst our biotech peers, combining successful commercial franchises, exciting late and early stage assets and the financial strength to capitalize on these opportunities |
| As you can see on the slide, ACP-204's profile could represent a significant improvement over an already strong product profile for pimavanserin |
| Before getting into the details of the study, I'd like to note that the PWS community has shown an incredibly high level of enthusiasm for this opportunity and interest in our study |
| On the formulation patents, in the fall, we also won a Markman Ruling in that case, which puts us in a favorable position, advancing into the Trial Court that is scheduled for December of this year, hearing, or excuse me, trial scheduled for December this year |
| We feel like we're in a very good position there |
| In addition to our commercial products, we have a strong pipeline of clinical programs providing us with several opportunities to further expand our growth |
| And beyond that, we have a rich pipeline of early stage, disclosed and undisclosed programs that position us for future growth |
| This sector represents an additional important growth opportunity as we continue to increase our breadth and depth in these institutions |
| These efforts have allowed us to grow new patient starts faster than the market |
| Our penetration, while we don't speak to absolutes is the highest in COEs, but we still have ample opportunity to grow new patient share in COEs, then followed by the high-volume institutions and then the community thereafter |
| This has also enabled us to rapidly gain real world insights that we've been able to use to further educate the medical and caregiver communities |
| We anticipate this will drive meaningful revenue growth well beyond this year |
| As the first drug approved for the treatment of Rett syndrome, we've experienced strong interest and demand from Rett families |
| As we've previously reported, this strong interest produced a surge of new patient starts in the first four months of the launch, followed by a demand curve that is much closer to our prelaunch expectations and the linear shaped curve we typically see in rare disease drugs |
| And yes, I think we have ample opportunity to continue to grow our penetration |
| This surge has produced multiple benefits |
| It's enabled us to reach a critical mass of experience in the medical and caregiver communities dramatically faster than we otherwise would have |
| With an estimated 5000 diagnosed Rett patients in the United States and a prevalent population of 6000 to 9000, there is a substantial opportunity in front of us to bring the benefits of this therapy to many more patients |
| Statement |
|---|
| Significant slowdown driven by lack of COE, Rett patient days and Rett patient visits |
| This resulted in delays in patients receiving their first paid shipments in the New Year |
| In January, we saw a decline in new prescriptions written, driven by seasonal and significant decline in Rett clinic visits following the holiday period, where approximately 50% of COEs had either no clinic days or reduced clinic days available |
| And just to give a little further context, as we described, we had a seasonal decline in January, and as a consequence fewer patients initiated therapy |
| The one place where there was a slowdown in new patient starts was January |
| Negative symptoms of schizophrenia have proven to be an exceedingly difficult drug development challenge with multiple industry failures over several decades |
| Negative symptoms are social withdrawal, restricted speech, lack of emotion, loss of motivation and blunted affect |
| In January, we saw a reduction in new patient prescriptions due to fewer office visits and Rett clinic days, together with reductions in conversion and refill rates as patients went through the payer re-enrollment process |
| In January, we also saw a reduction in refills and conversion rates due to typical beginning of the year reauthorization and re-enrollment processes |
| We have an extensive database with pimavanserin that they failed to show the clinical significance |
| We saw a much more significant impact, particularly in January, than we would have anticipated |
| In a rare disease space, things do bounce around more than others, and we saw a more pronounced effect of this seasonality than we anticipated |
| But I think since in the press release, they spelled out the reasons for the CRL, it's worth noting that the concerns were that there was only one study, and they need two |
| When we look backwards, it was a little lower over the course of the entire year |
| We only needed to win on one |
| I would also note that of all those patients, that 40% of patients that were on trofinetide or DAYBUE in clinical trials that have now rolled over, we've had zero dropouts from those patients since launch |
| Doug, two questions, one on DAYBUE or trofinetide in Europe and the other on negative symptoms |
| whose positive psychotic symptoms are adequately controlled with antipsychotic treatment, but who still suffer from persistent and uncontrolled negative symptoms, inhibiting their ability to lead a normal, productive life |
| In December in particular, we experienced higher than average refill rates as families prepared for the holidays and health plan changes or reauthorizations in the New Year |
| We have since seen a return of Rett clinic days in February, tracking back to historical levels and new patient prescription rates returning to the trends we observed prior to January |
Please consider a small donation if you think this website provides you with relevant information